2nd Quarter - Termination
IPOLICY SOLUTIONS for GENEDX, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Firm
Client
Income
$17,500
Expenses
—
Terminated
May 31, 2022
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 19, 2022 | $17,500 | Replaced |
| 2nd Quarter - Termination (this page) | Oct 17, 2022 | $17,500 | Replaced |
| 2nd Quarter - Amendment | May 15, 2023 | $17,500 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S.4348 - FDASLA Act of 2022
| Lobbyist | Covered position, as disclosed |
|---|---|
| MEGAN ANDERSON BROOKS | — |
| JENNIFER RACHEL LEIB | Fellow, Senate Health, Education, Labor, and Pensions Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.